Celltrion aims to commercialize insulin pen by 2025 - (The Investor via NewsPoints Desk)

  • Celltrion said it will begin developing its insulin pen biosimilar with medical device manufacturer Poonglim Pharmatech, aiming to launch the product in 2025, reported The Investor.

  • The firms intend to develop a pen-type injector that can hold up to 80 units per injection.

  • The Korea Evaluation Institute of Industrial Technology selected Celltrion’s insulin pipeline as a state-designated project.

  • The four-year development will require a budget of 4 billion won, of which 3 billion won will be backed by government funding.

To read more NewsPoints articles, click here.

Reference Articles